FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212917594> ?p ?o ?g. }

• W3212917594 abstract "There is a dearth of data characterizing patients receiving kidney replacement therapy (KRT) for kidney failure due to systemic lupus erythematosus (SLE) and their clinical outcomes. The aim of this study was to describe trends in incidence and prevalence of KRT among these patients as well as to compare their outcomes versus those of patients treated with KRT for diseases other than SLE.Retrospective cohort study based on kidney registry data.Patients recorded in 14 registries of patients receiving KRT that provided data to the European Renal Association Registry between 1992 and 2016.SLE as cause of kidney failure.Incidence and prevalence of KRT, patient survival while receiving KRT, patient and graft survival after kidney transplant, and specific causes of death.Kaplan-Meier methods and Cox regression models were fit to compare patient survival between the SLE and non-SLE groups, overall KRT, dialysis, and patient and graft survival after kidney transplant.In total, 1,826 patients commenced KRT for kidney failure due to SLE, representing an incidence of 0.80 per million population (pmp) per year. The incidence remained stable during the study period (annual percent change, 0.1% [95% CI, -0.6% to 0.8%]). Patient survival among patients with SLE receiving KRT was similar to survival in the comparator group (hazard ratio [HR], 1.11 [95% CI, 0.99-1.23]). After kidney transplant, the risk of death was greater among patients with SLE than among patients in the comparator group (HR, 1.25 [95% CI, 1.02-1.53]), whereas the risk of all-cause graft failure was similar (HR, 1.09 [95% CI, 0.95-1.27]). Ten-year patient overall survival during KRT and patient and graft survival after kidney transplant improved over the study period (HRs of 0.71 [95% CI, 0.56-0.91], 0.43 [95% CI, 0.27-0.69], and 0.60 [95% CI, 0.43-0.84], respectively). Patients with SLE receiving KRT were significantly more likely to die of infections (24.8%) than patients in the comparator group (16.9%; P < 0.001).No data were available on extrarenal manifestations of SLE, drug treatments, comorbidities, kidney transplant characteristics, or relapses of SLE.The prognosis of patients with SLE receiving KRT has improved over time. Survival of patients with SLE who required KRT was similar compared with patients who required KRT for other causes of kidney failure. Survival following kidney transplants was worse among patients with SLE." @default.
• W3212917594 created "2021-11-22" @default.
• W3212917594 creator A5010788605 @default.
• W3212917594 creator A5016762535 @default.
• W3212917594 creator A5017732700 @default.
• W3212917594 creator A5022293730 @default.
• W3212917594 creator A5025970803 @default.
• W3212917594 creator A5028156038 @default.
• W3212917594 creator A5034352676 @default.
• W3212917594 creator A5040848501 @default.
• W3212917594 creator A5043533263 @default.
• W3212917594 creator A5044287129 @default.
• W3212917594 creator A5046569845 @default.
• W3212917594 creator A5051943355 @default.
• W3212917594 creator A5052169042 @default.
• W3212917594 creator A5054328648 @default.
• W3212917594 creator A5054814300 @default.
• W3212917594 creator A5060577916 @default.
• W3212917594 creator A5071660720 @default.
• W3212917594 creator A5074367564 @default.
• W3212917594 creator A5077151959 @default.
• W3212917594 creator A5079152480 @default.
• W3212917594 creator A5081888215 @default.
• W3212917594 date "2021-11-01" @default.
• W3212917594 modified "2023-10-17" @default.
• W3212917594 title "Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry" @default.
• W3212917594 cites W1990742573 @default.
• W3212917594 cites W1997555314 @default.
• W3212917594 cites W2006728613 @default.
• W3212917594 cites W2020795504 @default.
• W3212917594 cites W2027615770 @default.
• W3212917594 cites W2038939596 @default.
• W3212917594 cites W2047799624 @default.
• W3212917594 cites W2065168884 @default.
• W3212917594 cites W2071602855 @default.
• W3212917594 cites W2078187985 @default.
• W3212917594 cites W2129400985 @default.
• W3212917594 cites W2137118285 @default.
• W3212917594 cites W2157519867 @default.
• W3212917594 cites W2158300364 @default.
• W3212917594 cites W2160382588 @default.
• W3212917594 cites W2291511906 @default.
• W3212917594 cites W2298285162 @default.
• W3212917594 cites W2890159104 @default.
• W3212917594 cites W2896578984 @default.
• W3212917594 cites W2912041785 @default.
• W3212917594 doi "https://doi.org/10.1053/j.ajkd.2021.09.016" @default.
• W3212917594 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34752912" @default.
• W3212917594 hasPublicationYear "2021" @default.
• W3212917594 type Work @default.
• W3212917594 sameAs 3212917594 @default.
• W3212917594 citedByCount "2" @default.
• W3212917594 countsByYear W32129175942022 @default.
• W3212917594 countsByYear W32129175942023 @default.
• W3212917594 crossrefType "journal-article" @default.
• W3212917594 hasAuthorship W3212917594A5010788605 @default.
• W3212917594 hasAuthorship W3212917594A5016762535 @default.
• W3212917594 hasAuthorship W3212917594A5017732700 @default.
• W3212917594 hasAuthorship W3212917594A5022293730 @default.
• W3212917594 hasAuthorship W3212917594A5025970803 @default.
• W3212917594 hasAuthorship W3212917594A5028156038 @default.
• W3212917594 hasAuthorship W3212917594A5034352676 @default.
• W3212917594 hasAuthorship W3212917594A5040848501 @default.
• W3212917594 hasAuthorship W3212917594A5043533263 @default.
• W3212917594 hasAuthorship W3212917594A5044287129 @default.
• W3212917594 hasAuthorship W3212917594A5046569845 @default.
• W3212917594 hasAuthorship W3212917594A5051943355 @default.
• W3212917594 hasAuthorship W3212917594A5052169042 @default.
• W3212917594 hasAuthorship W3212917594A5054328648 @default.
• W3212917594 hasAuthorship W3212917594A5054814300 @default.
• W3212917594 hasAuthorship W3212917594A5060577916 @default.
• W3212917594 hasAuthorship W3212917594A5071660720 @default.
• W3212917594 hasAuthorship W3212917594A5074367564 @default.
• W3212917594 hasAuthorship W3212917594A5077151959 @default.
• W3212917594 hasAuthorship W3212917594A5079152480 @default.
• W3212917594 hasAuthorship W3212917594A5081888215 @default.
• W3212917594 hasBestOaLocation W32129175941 @default.
• W3212917594 hasConcept C120665830 @default.
• W3212917594 hasConcept C121332964 @default.
• W3212917594 hasConcept C126322002 @default.
• W3212917594 hasConcept C167135981 @default.
• W3212917594 hasConcept C207103383 @default.
• W3212917594 hasConcept C2779541074 @default.
• W3212917594 hasConcept C2779978075 @default.
• W3212917594 hasConcept C2908647359 @default.
• W3212917594 hasConcept C44249647 @default.
• W3212917594 hasConcept C50382708 @default.
• W3212917594 hasConcept C61511704 @default.
• W3212917594 hasConcept C71924100 @default.
• W3212917594 hasConcept C72563966 @default.
• W3212917594 hasConcept C99454951 @default.
• W3212917594 hasConceptScore W3212917594C120665830 @default.
• W3212917594 hasConceptScore W3212917594C121332964 @default.
• W3212917594 hasConceptScore W3212917594C126322002 @default.
• W3212917594 hasConceptScore W3212917594C167135981 @default.
• W3212917594 hasConceptScore W3212917594C207103383 @default.
• W3212917594 hasConceptScore W3212917594C2779541074 @default.
• W3212917594 hasConceptScore W3212917594C2779978075 @default.
• W3212917594 hasConceptScore W3212917594C2908647359 @default.
• W3212917594 hasConceptScore W3212917594C44249647 @default.

• next